-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
FDA orphan drug designation can help accelerate the clinical development and registration of drugs in the United States
Dr.
Dr.
About FDA Orphan Drug Designation
Orphan Drug Designation (ODD) is a designation granted by the FDA's Office of Orphan Products Development (OOPD) to eligible drugs (including biological products) for the prevention, treatment, and diagnosis of rare diseases.
About Multiple Myeloma
Multiple myeloma (MM), one of the most common blood cancers, is a malignant disease of abnormal proliferation of clonal plasma cells
According to the Frost & Sullivan report:
- The number of new cases of MM in the United States increased from 30,300 in 2016 to 32,300 in 2020 and is expected to increase to 37,800 in 2025
IBI326 is an innovative product candidate jointly developed by Innovent and Reindeer Medical Pharma
About Innovent
"Begins with faith, achieves in action", and developing high-quality biological drugs affordable to the common people is the ideal and goal of Innovent
Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model
Innovent Bio has established a high-end biopharmaceutical development and industrialization talent team with international advanced level, including many returnee experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center and Hanmi in South Korea.
statement:
1.
2.
3.
About Reindeer Medical
Reindeer Medical is an innovative biopharmaceutical company focusing on the development and industrialization of cellular drugs and antibody drugs
With a strong executive management team, rich product pipeline, and unique innovative R&D and business models, Reindeer Medical aspires to become an influential innovative pharmaceutical company in the industry, bringing innovative drugs that truly solve clinical pain points and have market competitiveness to the market.
Innovent Forward-Looking Statements
Information published in this press release may contain certain forward-looking statements
.
These statements are inherently subject to considerable risk and uncertainty
.
The use of words such as "anticipates," "believes," "forecasts," "expects," "intends," and other similar words in relation to the Company is intended to identify forward-looking statements
.
The Company undertakes no obligation to continually update these forward-looking statements
.These forward-looking statements are based on the Company's management's current beliefs, assumptions, expectations, estimates, projections and understanding of future events at the time the statements are made
.
These statements are not guarantees for future development and are subject to risks, uncertainties and other factors, some of which are beyond the control of the company and are difficult to predict
.
Accordingly, actual results may differ materially from those contained in forward-looking statements as a result of future changes and developments in our business, competitive environment, political, economic, legal and social conditions
.The Company, its directors and employee agents disclaim (a) any obligation to correct or update the forward-looking statements contained in this website; and (b) any responsibility
.
